What Is Somatostatin Studied For? Research Areas, Per the Literature

Somatostatin is a short regulatory peptide produced in the hypothalamus, pancreatic delta cells, gut and other tissues, where it acts through five G protein coupled receptor subtypes to inhibit the release of several hormones. The question of what somatostatin is "used for" is answered here strictly as what it has been studied for in the published literature. Somatostatin is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any decision involving a prescription product.

One structural point shapes almost every research area below: native somatostatin has a very short circulating half life, so the great majority of clinical investigation has been carried out with longer acting synthetic analogs such as octreotide, lanreotide and pasireotide rather than with the natural peptide. A 2020 review of somatostatin analogs in clinical practice described this analog based landscape, covering receptor subtype pharmacology and the conditions in which analogs have been evaluated (PMID 32121432). Background on the peptide itself is collected on the somatostatin learn hub.

Research Areas at a Glance

1. Acromegaly and Growth Hormone Secretion

The best established clinical research area for somatostatin pharmacology is suppression of growth hormone secretion in acromegaly, a condition usually driven by a growth hormone secreting pituitary adenoma. The 2020 clinical practice review set out how somatostatin analogs bind predominantly to receptor subtypes 2 and 5 and how this receptor profile underpins their investigation in pituitary and neuroendocrine disease (PMID 32121432).

The ACROFAST study, a prospective human study in patients with acromegaly, tested whether treatment selection guided by predictive biomarkers performed differently from a conventional approach in which a first generation somatostatin analog is given to all patients; researchers reported that the biomarker guided, personalised strategy produced a higher rate of disease control over the study period than the conventional sequence (PMID 38943661). That trial is notable because it illustrates a broader theme in the field: response to somatostatin receptor directed treatment varies between tumours, and receptor expression is one of the factors investigators have examined to explain the variation (PMID 38943661).

Non-functioning pituitary adenomas

Beyond hormone secreting tumours, a human imaging study evaluated gallium 68 DOTATATE positron emission tomography in patients with clinically non-functioning pituitary macroadenomas and reported measurable somatostatin receptor directed tracer uptake in these lesions, which the authors framed as a question of whether receptor imaging could add information in tumours that do not oversecrete hormones (PMID 34191241).

2. Neuroendocrine Tumours and Antiproliferative Research

The second large research area concerns whether somatostatin receptor activation slows tumour growth rather than only controlling hormone related symptoms. A 2010 review of the antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumours summarised direct receptor mediated mechanisms, such as cell cycle arrest and apoptosis signalling in tumour cells, alongside indirect mechanisms including suppression of growth factors and effects on angiogenesis (PMID 20572298).

On the clinical side, a 2017 analysis of the CLARINET phase 3 trial in patients with enteropancreatic neuroendocrine tumours described prolonged progression free survival with a long acting somatostatin analog compared with placebo, and discussed how that result moved analogs from symptom control into the antitumour setting (PMID 28550464). A 2021 review of antiproliferative systemic therapies for metastatic small bowel neuroendocrine tumours placed somatostatin analogs within a wider treatment sequence that also includes targeted agents and radionuclide therapy in human practice (PMID 34185197). A 2025 case based evidence review of pancreatic neuroendocrine tumours similarly described somatostatin receptor directed options among the strategies evaluated in human disease management (PMID 40568033).

How widely are the receptors expressed?

Because every receptor directed strategy depends on target presence, a 2022 systematic review assessed somatostatin receptor expression across a broad range of neoplasms using human tissue data and reported that expression is not confined to classical neuroendocrine tumours but varies considerably by tumour type and receptor subtype (PMID 35890290). The authors of that systematic review framed the variability as a reason that receptor status, rather than tumour label alone, has been studied as the selection criterion for receptor targeted approaches (PMID 35890290).

3. Somatostatin Receptor Imaging

A distinct research area uses somatostatin analogs not as treatment but as carriers for diagnostic radionuclides. A 2023 clinical review of lung neuroendocrine neoplasms described somatostatin receptor positron emission tomography as a diagnostic tool used in human patients to characterise disease and to select candidates for receptor directed therapy (PMID 36585338).

Tracer development itself has been studied from bench to clinic. A 2020 paper on a fluorinated octreotide derivative, [18F]FET-betaAG-TOCA, reported the design and preclinical evaluation of the compound followed by clinical translation in human imaging, with the authors describing the rationale for a fluorine 18 labelled alternative to gallium 68 based agents (PMID 32252406). The pituitary imaging study described above belongs to the same research area (PMID 34191241).

4. Peptide Receptor Radionuclide Therapy

Peptide receptor radionuclide therapy attaches a therapeutic radionuclide to a somatostatin analog so that radiation is delivered to receptor expressing cells. The 2023 lung neuroendocrine neoplasm review covered both the imaging and the therapeutic arms of this approach in human patients and described the paired diagnostic and therapeutic use of receptor binding analogs (PMID 36585338). The 2021 small bowel neuroendocrine tumour review likewise included radionuclide therapy among antiproliferative options studied in metastatic human disease (PMID 34185197).

5. Retinal Inflammation and Neurodegeneration: Preclinical Only

Outside oncology and endocrinology, somatostatin has been investigated in the eye. A 2020 animal study applied somatostatin topically in an experimental model of diabetes and reported reductions in markers of retinal inflammation and neurodegeneration compared with control treatment, with the authors positioning topical delivery as a way to reach the retina without systemic exposure (PMID 32784955). This is animal evidence. The verified literature set for this page contains no human trial of topical somatostatin for diabetic retinal disease, so the finding should be read as preclinical and not as a demonstrated clinical outcome (PMID 32784955).

6. Nanoparticle and Drug Delivery Targeting

A 2018 review examined somatostatin receptors as active targeting sites for nanoparticles, summarising preclinical work in which analog decorated carriers were directed toward receptor expressing cells and tumours (PMID 30416362). The review described this as an emerging delivery strategy rather than established clinical practice (PMID 30416362).

Where the Evidence Is Weak, Preclinical or Absent

Several uses associated with somatostatin in general interest material are not supported by the verified literature set behind this page.

• Body composition, fat loss or athletic performance. No study in this citation set examined somatostatin or its analogs for body composition, weight change or exercise performance in healthy people. The clinical practice review of somatostatin analogs confined its scope to hormone secreting and neuroendocrine conditions (PMID 32121432).
• Anti-ageing or longevity. No human or animal longevity data appear in the cited papers; the antiproliferative work that exists was conducted in tumour biology contexts rather than in healthy ageing models (PMID 20572298).
• General growth hormone suppression in people without pituitary disease. The prospective acromegaly research cited here enrolled patients with acromegaly, not healthy volunteers, so its findings do not extend to people without that diagnosis (PMID 38943661).
• Native somatostatin as a stand alone long term therapy. The clinical literature in this set is dominated by synthetic analogs, which were developed because of the pharmacokinetic limitations of the natural peptide (PMID 32121432).

Where a question is not answered by published research, the accurate statement is that the evidence is absent, not that the compound failed or succeeded.

Somatostatin and Its Analogs: What Studies Report

Adverse event reporting in the verified set is limited and belongs to analog pharmacology rather than to native somatostatin. The 2020 clinical practice review of somatostatin analogs addressed efficacy together with tolerability considerations across the conditions in which the analogs have been studied, and is the appropriate source for readers seeking the safety discussion that accompanies those indications (PMID 32121432). The CLARINET analysis discussed the antitumour result in the context of a randomised placebo controlled trial design, where safety monitoring forms part of the trial framework (PMID 28550464). The 2020 animal eye study reported outcomes in an experimental diabetes model and did not provide human safety data (PMID 32784955). No specific adverse event rates are stated on this page because the verified papers listed below are the only permitted sources and detailed event tables are outside the scope summarised here.

Reading the Evidence Base

Three practical distinctions help when interpreting what somatostatin has been studied for. First, native peptide versus analog: most clinical conclusions come from analogs (PMID 32121432). Second, diagnostic versus therapeutic use: receptor imaging and receptor targeted radionuclide therapy share a molecular target but answer different questions (PMID 36585338). Third, species and setting: an effect reported in an experimental animal model has not been shown in people (PMID 32784955).

Somatostatin is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician before acting on any health information. Nothing here describes how any substance should be obtained or administered.

References

• Somatostatin Analogs in Clinical Practice: a Review (International Journal of Molecular Sciences, 2020)
• Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours (Current Treatment Options in Oncology, 2021)
• Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review (Pharmaceutics, 2022)
• Pancreatic Neuroendocrine Tumors: A Case-Based Evidence Review (World Journal of Gastrointestinal Pathophysiology, 2025)
• Effect of Topical Administration of Somatostatin on Retinal Inflammation and Neurodegeneration in an Experimental Model of Diabetes (Journal of Clinical Medicine, 2020)
• Antiproliferative Effect of Somatostatin Analogs in Gastroenteropancreatic Neuroendocrine Tumors (World Journal of Gastroenterology, 2010)
• Personalized Medicine in Acromegaly: The ACROFAST Study (The Journal of Clinical Endocrinology and Metabolism, 2024)
• Diagnosis and Treatment of Lung Neuroendocrine Neoplasms: Somatostatin Receptor PET Imaging and Peptide Receptor Radionuclide Therapy (PET Clinics, 2023)
• 68Ga-DOTATATE PET Imaging in Clinically Non-Functioning Pituitary Macroadenomas (European Journal of Hybrid Imaging, 2020)
• Anti-tumoral Effects of Somatostatin Analogs: a Lesson from the CLARINET Study (Journal of Endocrinological Investigation, 2017)
• [18F]FET-betaAG-TOCA: The Design, Evaluation and Clinical Translation of a Fluorinated Octreotide (Cancers, 2020)
• Somatostatin Receptors as a New Active Targeting Sites for Nanoparticles (Saudi Pharmaceutical Journal, 2018)